表紙:C反応性タンパク(CRP)の世界市場 2019年~2023年
市場調査レポート
商品コード
843037

C反応性タンパク(CRP)の世界市場 2019年~2023年

Global C-Reactive Protein Test Market 2019-2023

出版日: | 発行: TechNavio (Infiniti Research Ltd.) | ページ情報: 英文 119 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.86円
C反応性タンパク(CRP)の世界市場 2019年~2023年
出版日: 2019年05月06日
発行: TechNavio (Infiniti Research Ltd.)
ページ情報: 英文 119 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

慢性疾患の罹患率の上昇が、C反応性タンパク(CRP)市場の成長を促進する要因のひとつとされています。米国において10人中7人が糖尿病、脳卒中、がん、関節炎などの慢性疾患を原因に死亡しています。また、重大な健康問題として懸念される自己免疫疾患は、予測期間中のC反応性タンパク(CRP)検査の需要をさらに高めるとされています。途上国におけるHIVの罹患率の上昇もC反応性タンパク(CRP)検査の需要を押し上げ、結果、市場の成長を後押ししています。世界のC反応性タンパク(CRP)市場は、2023年にかけて1%を超えるCAGRで推移すると予測されています。

当レポートでは、世界のC反応性タンパク(CRP)市場を調査し、市場の概要、エンドユーザー・地域別の市場規模の推移と予測、市場の成長要因および課題の分析、市場動向、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

第1章 エグゼクティブサマリー

第2章 レポート概要

第3章 市場状況

  • 市場のエコシステム
  • 市場の特徴
  • 市場セグメンテーション分析

第4章 市場規模

  • 市場の定義
  • 市場規模
  • 市場規模の推移と予測

第5章 ファイブフォース分析

  • 買い手の交渉力
  • 供給企業の交渉力
  • 新規参入業者の脅威
  • 代替品の脅威
  • 競争企業間の敵対関係
  • 市況

第6章 市場セグメンテーション:エンドユーザー別

  • 市場区分:エンドユーザー別
  • 市場比較:エンドユーザー別
  • 病院
  • 臨床検査室
  • その他
  • 市場機会:エンドユーザー別

第7章 顧客情勢

第8章 市場情勢:地域別

  • 市場区分:地域別
  • 市場比較:地域別
  • 北米
  • 欧州
  • アジア
  • その他の地域
  • 市場牽引国
  • 市場機会

第9章 意思決定の枠組み

第10章 成長要因と課題

  • 市場成長要因
  • 市場の課題

第11章 市場動向

第12章 ベンダー情勢

  • 概要
  • 創造的破壊の状況

第13章 ベンダー分析

  • 対象ベンダー
  • ベンダー分類
  • ベンダーの市場ポジショニング
  • Abbott
  • Danaher
  • F Hoffmann-La Roche Ltd
  • Merck KGaA
  • Thermo Fisher Scientific Inc.

第14章 付録

  • 調査方法
  • 略語一覧
  • ベンダーのポジショニング

第15章 TECHNAVIOについて

目次
Product Code: IRTNTR31207

About this market

The rising prevalence of chronic diseases is one of the key factors expected to trigger the market growth during the forecast period. Chronic diseases including diabetes, stroke, cancer, arthritis, and others are responsible for seven out of 10 deaths among the people in the US. In addition, autoimmune diseases are a key health concern, further, driving the demand for CRP tests during the forecast period. The ability for diagnosing diseases increases significantly using CRP tests, while impacting the market growth positively during the forecast period. Technavio's analysts have predicted that the C-reactive protein test market will register a CAGR of over 1% by 2023.

Market Overview

Rising incidence of HIV in developing countries

The increasing incidence of HIV infections, especially in developing countries, posed a challenge to the economy. This has further necessitated the need for monitoring HIV disease activity through low-cost techniques such as CRP testing. HIV is a virus that enters the blood, and attacks and destroys the body's immune system, which results in the development of AIDS. Importance of evaluating the CRP level in HIV affected patients through hs-CRP assays has increased the demand for CRP testing and is expected to increase further during the forecast period, boosting the market growth.

Increasing data integrity issues

CRP testing data relies on recording observation, in which error may occur, resulting in manipulation and wrong information of results. This reduces the reliability of tests, which hinders market growth.

For the detailed list of factors that will drive and challenge the growth of the C-reactive protein test market during 2019-2023, view our report.

Competitive Landscape

The market appears to be moderately concentrated and with the presence of a few market players. Vendors are offering high-end innovative products that are using protein analysis to detect chronic diseases. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY END-USER

  • Market segmentation by end-user
  • Comparison by end-user
  • Hospitals - Market size and forecast 2018-2023
  • Clinical laboratories - Market size and forecast 2018-2023
  • Others - Market size and forecast 2018-2023
  • Market opportunity by end-user

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Abbott
  • Danaher
  • F Hoffmann-La Roche Ltd
  • Merck KGaA
  • Thermo Fisher Scientific Inc.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of vendor positioning

PART 15: EXPLORE TECHNAVIO

List of Exhibits

  • Exhibit 01: Global healthcare market
  • Exhibit 02: Segments of global healthcare market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Market definition - Inclusions and exclusions checklist
  • Exhibit 06: Market size 2018
  • Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 09: Five forces analysis 2018
  • Exhibit 10: Five forces analysis 2023
  • Exhibit 11: Bargaining power of buyers
  • Exhibit 12: Bargaining power of suppliers
  • Exhibit 13: Threat of new entrants
  • Exhibit 14: Threat of substitutes
  • Exhibit 15: Threat of rivalry
  • Exhibit 16: Market condition - Five forces 2018
  • Exhibit 17: End-user - Market share 2018-2023 (%)
  • Exhibit 18: Comparison by end-user
  • Exhibit 19: Hospitals - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 20: Hospitals - Year-over-year growth 2019-2023 (%)
  • Exhibit 21: Clinical laboratories - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 22: Clinical laboratories - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: Others - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 24: Others - Year-over-year growth 2019-2023 (%)
  • Exhibit 25: Market opportunity by end-user
  • Exhibit 26: Customer landscape
  • Exhibit 27: Market share by geography 2018-2023 (%)
  • Exhibit 28: Geographic comparison
  • Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 30: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 33: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 34: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 35: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 36: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 37: Key leading countries
  • Exhibit 38: Market opportunity
  • Exhibit 39: Impact of drivers and challenges
  • Exhibit 40: Vendor landscape
  • Exhibit 41: Landscape disruption
  • Exhibit 42: Vendors covered
  • Exhibit 43: Vendor classification
  • Exhibit 44: Market positioning of vendors
  • Exhibit 45: Abbott - Vendor overview
  • Exhibit 46: Abbott - Business segments
  • Exhibit 47: Abbott - Organizational developments
  • Exhibit 48: Abbott - Geographic focus
  • Exhibit 49: Abbott - Segment focus
  • Exhibit 50: Abbott - Key offerings
  • Exhibit 51: Danaher - Vendor overview
  • Exhibit 52: Danaher - Business segments
  • Exhibit 53: Danaher - Organizational developments
  • Exhibit 54: Danaher - Geographic focus
  • Exhibit 55: Danaher - Segment focus
  • Exhibit 56: Danaher - Key offerings
  • Exhibit 57: F Hoffmann-La Roche Ltd - Vendor overview
  • Exhibit 58: F Hoffmann-La Roche Ltd - Product segments
  • Exhibit 59: F Hoffmann-La Roche Ltd - Organizational developments
  • Exhibit 60: F Hoffmann-La Roche Ltd - Geographic focus
  • Exhibit 61: F Hoffmann-La Roche Ltd - Segment focus
  • Exhibit 62: F Hoffmann-La Roche Ltd - Key offerings
  • Exhibit 63: Merck KGaA - Vendor overview
  • Exhibit 64: Merck KGaA - Business segments
  • Exhibit 65: Merck KGaA - Organizational developments
  • Exhibit 66: Merck KGaA - Geographic focus
  • Exhibit 67: Merck KGaA - Segment focus
  • Exhibit 68: Merck KGaA - Key offerings
  • Exhibit 69: Thermo Fisher Scientific Inc. - Vendor overview
  • Exhibit 70: Thermo Fisher Scientific Inc. - Business segments
  • Exhibit 71: Thermo Fisher Scientific Inc. - Organizational developments
  • Exhibit 72: Thermo Fisher Scientific Inc. - Geographic focus
  • Exhibit 73: Thermo Fisher Scientific Inc. - Segment focus
  • Exhibit 74: Thermo Fisher Scientific Inc. - Key offerings
  • Exhibit 75: Validation techniques employed for market sizing
  • Exhibit 76: Definition of vendor positioning